Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity? Barchart · Feb 19
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now? Barchart · Dec 24, 2025
What's Going On With Recursion Pharmaceuticals Stock On Wednesday? Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Benzinga · Oct 8, 2025
Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift. Barchart · Sep 25, 2025
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. Benzinga · Aug 5, 2025
Why Is Recursion Pharma Stock Surging On Monday? In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood). Benzinga · Jul 21, 2025
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares? Barchart · Apr 11, 2025
Biotechs on the Brink: 2 Stocks With Huge Potential BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out. MarketBeat · Feb 14, 2025
1 AI Biotech Stock That Just Scored a Major Milestone Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process. Barchart · Oct 5, 2024
AI Could Power Up These 2 Biotech Stocks AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity. Barchart · Jul 10, 2024
Should You Buy the Dip in This AI-Driven Drug Stock? Down 76% from all-time highs, is this AI-powered drug stock a good buy right now? Barchart · Jul 4, 2024
3 Small-Cap Stocks to Invest in AI Drug Development As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now. Barchart · May 22, 2024
1 AI Growth Stock With 54% Upside Potential Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood. Barchart · Mar 14, 2024
Nvidia Just Invested $76 Million in 1 Cathie Wood Stock Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund. Barchart · Feb 22, 2024
Barchart · Feb 21, 2024 Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.
Barchart · Dec 1, 2023 1 Cathie Wood Stock With Over 100% Upside, According to Analysts This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.